Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.

Correction: BMC Med 20, 187 (2022)

https://doi.org/10.1186/s12916-022-02356-7

After publication of the original article [1], it came to the authors’ attention that there is an error in the originally-published version of Additional file : Table S2 and Table S3. In the univariate and multivariate regression analyses of the association between baseline plasma or tumor tissue IL-6 levels and clinical factors for the prediction of progression-free survival (PFS), the results of smoking history were lost.

The correct version of Additional file : Table S2 and Table S3 is published in this erratum.

Additional file 1: Table S2. Univariate and multivariate regression analyses of the association between baseline plasma IL-6 levels and clinical factors for the prediction of PFS. Table S3. Univariate and multivariate regression analyses of the relationship between baseline tumor tissue IL-6 levels and clinical factors for the prediction of PFS.